中期18F-FDG PET/CT在预测转移性黑色素瘤伊匹木单抗治疗反应中的作用
研究纳入41例不可切除转移性黑色素瘤患者,在伊匹木单抗治疗前及初始两周期后行全身18F-FDG PET/CT,分别按EORTC 1999标准和PERCIMT评估中期PET/CT,以中位21.4个月随访的最佳临床反应为参照。PERCIMT预测临床获益的灵敏度93.6%高于EORTC的64.5%(p=0.004),特异度70.0%与90.0%间无显著差异(p=0.5)。
要点
- PERCIMT预测临床获益的灵敏度93.6%,高于EORTC标准的64.5%(p=0.004)。
- 两标准特异度分别为70.0%与90.0%,差异无统计学显著(p=0.5)。
- 两标准间一致性差(McNemar检验p=0.001,kappa=0.46)。
核心结论
- 在转移性黑色素瘤患者中,应用新近提出的PERCIMT评估中期18F-FDG PET/CT,较EORTC标准能更敏感地预测免疫治疗的最终临床反应。
研究设计与样本
- 研究纳入41例不可切除转移性黑色素瘤、计划接受伊匹木单抗治疗的患者。
- 在伊匹木单抗治疗开始前(基线PET/CT)及初始两周期后(中期PET/CT)行全身18F-FDG PET/CT。
- 以中位21.4个月(范围6.3-41.9个月)评估的最佳临床反应为参照。
主要发现
- 按最佳临床反应分为临床获益组31例(含疾病稳定、部分缓解和完全缓解)与无临床获益组10例(含疾病进展)。
- 按EORTC标准,中期PET/CT示进展性代谢病20例、稳定性代谢病11例、部分代谢缓解8例、完全代谢缓解2例。
- 按PERCIMT,中期PET/CT示进展性代谢病9例、稳定性代谢病24例、部分代谢缓解6例、完全代谢缓解2例。
- EORTC标准预测最佳临床反应的灵敏度64.5%、特异度90.0%、阳性预测值95.2%、阴性预测值45.0%、准确率70.7%。
- PERCIMT预测最佳临床反应的灵敏度93.6%、特异度70.0%、阳性预测值90.6%、阴性预测值77.8%、准确率87.8%。
关键数值与推荐
- McNemar检验示PERCIMT灵敏度显著高于EORTC标准(p=0.004),特异度无显著差异(p=0.5)。
- 两标准间一致性差(McNemar检验p=0.001,kappa=0.46)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of the present study was to assess the value of interim 18F-FDG PET/CT performed after the first two cycles of ipilimumab treatment in the prediction of the final clinical response to this type of immunotherapy. METHODS: The study group comprised 41 patients with unresectable metastatic melanoma scheduled for ipilimumab therapy. Whole-body 18F-FDG PET/CT was performed before the start of ipilimumab treatment (baseline PET/CT) and after the initial two cycles of ipilimumab treatment (interim PET/CT). Evaluation of patient response to treatment was based on the European Organization for Research and Treatment of Cancer (EORTC) 1999 criteria for PET as well as the recently proposed PET Response Evaluation Criteria for Immunotherapy (PERCIMT). The patients' best clinical response, assessed at a median of 21.4 months (range 6.3-41.9 months) was used as reference. RESULTS: According to their best clinical response, the patients were divided into two groups: those showing clinical benefit (CB) including stable disease, partial response and complete response (31 patients), and those showing no clinical benefit (no-CB including progressive disease (10 patients). According to the EORTC criteria, interim PET/CT demonstrated progressive metabolic disease (PMD) in 20 patients, stable metabolic disease (SMD) in 11 patients, partial metabolic response (PMR) in 8 patients, and complete metabolic response (CMR) in 2 patients. According to the PERCIMT, interim PET/CT demonstrated PMD in 9 patients, SMD in 24 patients, PMR in 6 patients and CMR in 2 patients. On the basis of the interim PET, the patients were divided in a similar manner to the division according to clinical response into those showing metabolic benefit (MB) including SMD, PMR and CMR, and those showing no metabolic benefit (no-MB) including PMD. According to this dichotomization, the EORTC criteria showed a sensitivity (correctly predicting CB) of 64.5%, a specificity (correctly predicting no-CB) of 90.0%, a positive predictive value (PPV) of 95.2%, a negative predictive value (NPV) of 45.0% and an accuracy of 70.7% in predicting best clinical response. The PERCIMT showed a sensitivity of 93.6%, a specificity of 70.0%, a PPV of 90.6%, a NPV of 77.8% and an accuracy of 87.8%. The McNemar test showed that the PERCIMT had a significantly higher sensitivity than EORTC criteria (p = 0.004), while there was no significant difference in specificity (p = 0.5). The agreement between the two sets of criteria was poor (McNemar test p = 0.001, and accordingly kappa = 0.46). CONCLUSION: The application of the recently proposed PERCIMT to interim 18F-FDG PET/CT provides a more sensitive predictor of final clinical response to immunotherapy than the application of the EORTC criteria in patients with metastatic melanoma.
引用
- Sachpekidis C, Anwar H, Winkler J, et al. The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2018. PMID: 29478079. doi:10.1007/s00259-018-3972-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。